Tracey Weisberg, MD
Hematology & Oncology · Westbrook, MENPI 1871564724
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $29,465 of the $30,556 with a category attached, or 96.4%. Daiichi Sankyo Inc. accounts for 77.1% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2020 at $22,020 and has fallen 61.3% since, to $8,513 in 2021.
Across 22 payments — averaging $1388.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$24K
- Lilly USA, LLC$7K
- AbbVie$12
- Gilead$12
- Amgen$11
Across 6 payments — averaging $13,019 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Radius Health, Inc.$77K
- Genentech, Inc.$674
What the payments were for
- Consulting fees$29,46596%
- Travel & lodging$8813%
- Food & beverage$1861%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 17 | $23,546 |
| Lilly USA, LLC | 2 | $6,975 |
| AbbVie | 1 | $12 |
| Gilead | 1 | $12 |
| Amgen | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Enhertu$23,371
How this compares
$30,556 in reported general payments places this provider in the 85th percentile of 60 hematology & oncology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Westbrook
- Matthew DuganWestbrook$577K
- John WintersWestbrook$341K
- Eleni NackosWestbrook$79K
- Christian ThomasWestbrook$54K
- Devon EvansWestbrook$31K
- Daniel RauschWestbrook$20K
- Patrick BolandWestbrook$20K
- Owen PickusWestbrook$1K
- Chiara BattelliWestbrook$929
- Helen RyanKennebunk$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.